CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4RΞ±/STAT3 pathway and stabilizing membranous SLC7A11
21 August 2026 at 08:00
Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00650-0
CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4RΞ±/STAT3 pathway and stabilizing membranous SLC7A11